Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20943941 | 0.98 | MAPT (0.56) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL4034491 | 0.88 | MAPT (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL11326977 | 0.86 | MAPT (0.57) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL15862062 | 0.86 | KDM4E (0.62) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL15862210 | 0.86 | LOXL2 (0.59) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL8422569 | 0.83 | KDM4E (0.54) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL17083281 | 0.83 | LOXL2 (0.56) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL29934082 | 0.83 | LOXL2 (0.56) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL19068382 | 0.82 | KDM4E (0.53) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL23501653 | 0.81 | LOXL2 (0.54) | MAPTKDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885KDM4E 3737/4885ALDH1A1 4011/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885KDM4E 3737/4885ALDH1A1 4011/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885KDM4E 3737/4885ALDH1A1 4011/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | MAPT 4665/4885KDM4E 3737/4885ALDH1A1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.